[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-pleural-mesothelioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-pleural-mesothelioma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,75,100,128,155,182,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100498040","phase-1-integration-of-the-pd-l1-inhibitor-atezolizumab-and-wt1dc-vaccination-into-platinumpemetrexed-based-first-line-treatment-for-epithelioid-malignant-pleural-mesothelioma-100498040",false,"NCT05765084","Integration of the PD-L1 Inhibitor Atezolizumab and WT1\u002FDC Vaccination Into Platinum\u002FPemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","Immuno-MESODEC","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be eligible to participate in the study:\n\n* Signed informed consent\n* Diagnosis with histologically proven epithelioid unresectable MPM (stage I-IV)\n* Age ≥ 18 years at the time of signing informed consent\n* World Health Organization (WHO) performance status 0-1\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL (1500\u002FμL) without granulocyte colony- stimulating factor support\n  * Lymphocyte count ≥ 0.5 x 10\\^9\u002FL (500\u002FμL)\n  * Platelet count ≥ 100 x 10\\^9\u002FL (100,000\u002FμL) without transfusion\n  * Hemoglobin ≥ 90 g\u002FL (9 g\u002FdL) Patients may be transfused to meet this criterion\n  * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions:\n  * Patients with documented liver metastases: AST and ALT ≤ 5 x ULN\n  * Patients with documented liver or bone metastases: ALP ≤ 5 x ULN\n  * Total bilirubin ≤ 1.5 x ULN with the following exception:\n  * Patients with known Gilbert disease: total bilirubin ≤ 3 x ULN\n  * Creatinine ≤ 1.5 x ULN\n  * Albumin ≥ 25 g\u002FL (2.5 g\u002FdL)\n  * For patients not receiving therapeutic anticoagulation: prothrombin international normalized ration (PT-INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN\n* Negative Human Immunodeficiency Virus (HIV) test at screening\n* Negative hepatitis B surface antigen (HBsAg) test at screening\n* Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening\n\n  * The HBV DNA test will be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.\n* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test.\n* Willing and able to comply with the study protocol, as judged by the treating physician\n* Women of childbearing potential must have a negative serum or urine pregnancy test at the time of screening and agree to use effective contraception (\\\u003C1% failure rate per year) before, during and for at least five months after the last atezolizumab administration or at least hundred days after the last WT1\u002FDC vaccine administration (whichever takes longer). Men must agree to use effective contraception before, during and for at least hundred days after the last study treatment administration.\n\nExclusion Criteria:\n\nSubjects who fulfill any of the following criteria will not be eligible for admission into the study:\n\n* History of malignancy within 3 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases. Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:\n\n  * Measurable disease, per RECIST v1.1, must be present outside the CNS.\n  * The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.\n  * The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.\n  * The patient has no ongoing requirement for corticosteroids as therapy for CNS disease.\n  * If the patient is receiving anti-convulsant therapy, the dose is considered stable.\n  * Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).\n  * There is no evidence of interim progression between completion of CNS directed therapy and initiation of study treatment.\n  * Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy and\u002For surgery, with no need to repeat the screening brain scan.\n* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti-phospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:\n\n  * Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.\n  * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n    * Rash must cover \\\u003C 10% of body surface area\n    * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n    * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety\n* Prior treatment for MPM\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease (COPD) exacerbation) are eligible for the study.\n* Prior allogeneic stem cell or solid organ transplantation\n* Use of any investigational agent within 28 days before study enrollment\n* Pregnant or breastfeeding. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until at least hundred days after the last study treatment administration.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Current treatment with anti-viral therapy for HBV\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-α \\[TNF-α\\] agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) may be eligible for the study after Medical Monitor confirmation has been obtained.\n  * Patients who received mineralocorticoids (e.g., fludrocortisone), inhaled or low dose corticosteroids for COPD or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 drug-elimination half-lives of the drug, whichever is longer, prior to initiation of study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation\n* Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of atezolizumab, pemetrexed, cisplatin\u002Fcarboplatin and\u002For WT1\u002FDC vaccination, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","In this multicenter phase I\u002FII trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum\u002Fpemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum\u002Fpemetrexed-based chemotherapy with atezolizumab and WT1\u002FDC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.",[27],"Malignant Pleural Mesothelioma",[29,30,31,32],"Dendritic cell vaccination","Chemo-immunotherapy","Wilms' Tumor 1 (WT1)","Checkpoint inhibition","RECRUITING","2026-06-04",{"date":36,"type":37},"2026-06-05","ACTUAL",{"date":39,"type":37},"2023-02-24",{"date":41,"type":20},"2027-10",{"name":43,"class":44},"University Hospital, Antwerp","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100635235","comprehensive-oncogenomic-mapping-and-exploration-in-thoracic-and-head--neck-oncology-100635235","NCT07550049","Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology","COMETH Study: Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology","COMETH","Inclusion Criteria:\n\n* Ability of participant to understand this study, and participant willingness to sign a written informed consent. NOTE: Remote consenting allowed per IRB policy.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Males and\u002For females age ≥ 18 years\n* Diagnosis of one of the following:\n\n  1. Advanced stage (IIIB to IV) non-small cell lung cancer (all types including mixed histology, without actionable mutations)\n  2. Extensive-stage small cell lung cancer that are treatment naïve that will receive immunotherapy and chemotherapy\n  3. Recurrent or metastaƟc squamous cell head and neck cancers, squamous cell, HPV posiƟve or HPV negaƟve, treatment naïve that will start immunotherapy and chemotherapy\n  4. Malignant pleural mesothelioma that will be treated with immunotherapy and chemotherapy\n* Eligible to receive chemotherapy (plaƟnum based) with an immune checkpoint inhibitor (single or double agents).\n* Able to provide consent to obtain a blood sample, prior future genomic research of their samples.\n* Planning to start therapy in the next 28 days.\n\nExclusion Criteria:\n\n* Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements\n* Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation.\n* Advanced stage (IIIB to IV) non-small cell lung cancer with actionable mutations\n* Active viral infection (Hep C or B) requiring anti-viral therapy in the last 28 days. HIV patients on stable on anti-viral therapy able to receive therapy for the cancer are eligible to participate.\n* Active use of prednisone equivalent to more than 10mg\u002Fday\n* Second malignancy that requires systemic treatment at the time of consent",{"count":55,"type":20},110,"OBSERVATIONAL","This is an ancillary laboratory study to collect and bank blood and tissue samples. The biospecimens collected for this study will be invaluable for future research into predictive biomarkers and genomic alterations and their correlation with clinical outcomes.",[59,60,27],"Small Cell Lung Cancer","Head and Neck Cancer",[62,63,64],"Biobank","Blood bank","Tissue bank","NOT_YET_RECRUITING","2026-04-17",{"date":68,"type":37},"2026-04-24",{"date":70,"type":20},"2026-04",{"date":72,"type":20},"2029-04",{"name":74,"class":44},"University of Kansas Medical Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100489588","hemithoracic-irradiation-with-proton-therapy-in-malignant-pleural-mesothelioma-100489588","NCT05655078","Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma","HIT-Meso","Inclusion criteria:\n\n* Patients ≥18 years of age, with biopsy confirmed MPM and histological subtyping (epithelioid or non-epithelioid)\n* N0 or N1 and M0 disease\n* Written informed consent\n* Patient and local\u002Fregional MDT opt for active surveillance and deferral of SACT until clinical or radiological progression\n* WHO Performance Status 0-1\n* Disease confined to one hemithorax based on CT assessment\n* Adequate pulmonary function\n\n  * ≥ 40% predicted post-FEV1;\n  * ≥ 40% predicted DLCO\u002FTLCO\n* Agreement to travel to either proton beam therapy centres (i.e. UCLH or The Christie) if randomised to arm 2\n* Agreement to be followed up at a local HIT-Meso trial site\n* Patient likely able to complete PBT planning based on local assessment\n\nExclusion criteria:\n\n* Presence of metastatic or contralateral disease\n* Cytological diagnosis and\u002For undetermined histological subtype\n* Prior thoracic radiotherapy, chemotherapy, immunotherapy for MPM\n* Prior radical surgery for MPM (extrapleural pneumonectomy or extended pleurectomy decortication or pleurectomy decortication)\n* Initial systemic therapy or surgery is required and the patient and local\u002Fregional MDT do not opt for active surveillance\n* Involvement of contralateral or supraclavicular lymph nodes\n* T4 disease with invasion of the myocardium\n* N2 and\u002For M1 disease\n* Presence of new effusion that is not amenable to drainage\n* WHO Performance Status ≥ 2\n* Women who are pregnant or breast feeding\n* Current or previous malignant disease which may impact on the patient's life expectancy\n* Patient fitted with a pacemaker or implantable cardioverter-defibrillator (ICD)\\\\\n* Diagnosis of clinically significant interstitial lung disease (ILD), excluding mild fibrosis or incidental findings\n* Chronic non-malignant disease with an estimated three-year survival rate of less than 20%\n* Patient with prior thoracic \u002F abdominal radiotherapy for malignancy who was not discussed with sponsor before recruitment",{"count":83,"type":20},148,[85],"NA","Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).",[27],[89],"Proton beam therapy","2026-03-27",{"date":92,"type":37},"2026-03-30",{"date":94,"type":37},"2024-03-28",{"date":96,"type":20},"2029-09-30",{"name":98,"class":44},"University College, London",25,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100393247","phase-2-the-immunotherapy-pleural-5-ala-pdt-100393247","NCT04400539","The IMmunotherapy Pleural 5-ALA PDT","Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy Followed by Anti-PD-1 NIVOLUMAB in Patients With Malignant Pleural Mesothelioma - a Pilot Study","IMPALA","Inclusion Criteria:\n\n* ECOG Performance status (PS) 0-1 (WHO)\n* Unresectable Malignant Pleural Mesothelioma\n* suffering from unresectable MPM (n=20), relapsing after one or 2 lines of treatment with platinum-based doublet of chemotherapy (including pemetrexed) \\[Note: MPM patients having contra-indications for, or refusing chemotherapy may also be recruited\\], and candidate for palliative pleural procedure (i.e. thoracoscopy for pleurodesis by talc or by insertion of indwelled pleural catheter, IPC)\n* Documented progression after previous 1 or 2 lines of chemotherapy including Platinum\u002FPemetrexed chemotherapy\\*\n* Measurable disease according to modified RECIST 1.1. for MPM\n* Malignant pleural lesion assessed to be accessible by local PDT treatment during thoracoscopy, as validated by expert MTB (\"MESOCLIN\", Lille, France)\n* Histological diagnosis confirmed by national expert pathology panel (\"MESOPATH\" - Institut Léon Bérard, Lyon, France)\n* Weight loss \\\u003C10%\n* available tumor tissue (archival or fresh)\n* obtention of an informed written consent before any specific procedure of the study\n* Decision to treat the patient within this clinical trial taken during MPM dedicated multidisciplinary board (RCP MESOCLIN in France )\n* Patient affiliated to and covered by social security for standard care\n* Women of child-bearing potential must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 5 months after the final dose of investigational product\n* Women of child-bearing potential must have a negative pregnancy test within 24h before administration of investigational product\n* First line patients may also be recruited if they declined or if they have contra-indications for chemotherapy.\n\nExclusion Criteria:\n\n* lack of informed written consent; or refusal to sign or to participate\n* Pregnant, breastfeeding patients, and female patients of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 5 months after the last dose of nivolumab\n* Male patients who are unwilling or unable to use contraception methods for the duration of the study and for at least 7 months after the last dose of nivolumab\n* a previous treatment by anti-PD-1 or anti-PD-L1 antibodies for their cancer or any other cancer in the last 5 years\n* hypersensitivity to Nivolumab (anti-PD-1 antibodies)\n* contra-indications for 5-ALA or PDT\n* contra-indications for thoracoscopy (VATS)\n* any other comorbidity precluding the feasibility of the therapeutic protocol: uncontrolled cardiac failure, pulmonary hypertension, liver or kidney severe dysfunction (creatinin clearance \\\u003C60 ml\u002Fmin), uncontrolled infection, or other disease according to the investigator\n* other cancer treated within 5 years before inclusion except baso-cellular skin carcinoma or cervical \u002F bladder in situ carcinoma\n* inability to receive study information and to give informed consent\n* patient unable to have a clinical follow-up due to psychological, familial, social or geographical reasons\n* legal incapacity (people in jail), or under supervision (i.e. guardianship or curatorship)\n* treatment with experimental drug within 30 days before the start of the study",{"count":109,"type":20},20,[24],"Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma",[113,27],"Mesotheliomas Pleural",[115,116,117],"Immunotherapy","anti-PD-1","Photodynamic Therapy","2025-09-24",{"date":120,"type":37},"2025-09-25",{"date":122,"type":37},"2022-05-09",{"date":124,"type":20},"2026-05-09",{"name":126,"class":44},"University Hospital, Lille",1,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100519007","using-e-nose-technology-to-measure-response-to-treatment-in-people-with-malignant-pleural-mesothelioma-100519007","NCT06037941","Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma","Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates","Inclusion Criteria:\n\n* Aged 30-85 years\n* No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)\n* Recent diagnosis of MPM\n* Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection\n\nExclusion Criteria:\n\n* Aged \\\u003C30 or \\>85 years at the first outpatient visit\n* History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases","30 Years","85 Years",{"count":109,"type":20},[85],"The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.",[27],[142,143,144],"Breathprinting (E-Nose) Technology","MPM-Specific Volatile Organic Compounds","23-100","2025-09-18",{"date":147,"type":37},"2025-09-22",{"date":149,"type":37},"2023-09-08",{"date":151,"type":20},"2026-09",{"name":153,"class":44},"Memorial Sloan Kettering Cancer Center",7,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":181},"100356134","phase-1-apg-2449-in-patients-with-advanced-solid-tumors-100356134","NCT03917043","APG-2449 in Patients With Advanced Solid Tumors","A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and\u002For cytology and positive for ALK\u002FROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, esophageal cancer and ovarian cancer. Kind of patients with advanced tumors.\n\n   Expansion stage: cohort 1, patients with non-small cell lung cancer who have progressed or are intolerant to TKI therapy, including patients with second-generation ALK TKI, or either ROS1 TKI, or third-generation ALK inhibitor (lorlatinib, etc.) with pFAK expression (pFAK expression is subject to central laboratory results) of about 10 or above; Cohort 2, TKI-naïve patients with ALK\u002FROS1 fusion gene positive NSCLC. The molecular diagnosis results of the above patients can be confirmed by the investigator.\n2. ECOG Performance Status ≤ 1.\n3. Expectation of life ≥ 3 months.\n4. According to RECIST version 1.1, there is at least 1 measurable lesion.\n5. Adequate hematologic and bone marrow functions.\n6. Adequate renal and liver function.\n7. Normal cardiac function.\n8. Brain metastases with clinically controlled neurologic symptoms.\n9. Serum pregnancy test results of women of childbearing age were negative within 7 days before taking the first dose of study drug.\n10. Men, women of childbearing age (postmenopausal women must have been menopausal for at least 12 months before they can be considered infertile) and their partners voluntarily take the study drug for at least 30 days after signing the informed consent form and taking the study drug as deemed effective by the investigator Contraceptive measures\n11. Ability to understand and willingness to sign a written informed consent form\n12. Subjects must be willing and able to complete the research procedures and follow-up inspections.\n13. Subjects are required to provide fresh (for recurrent subjects only) or archived tumor tissue samples from within 28 days prior to treatment. If none of these specimens are available, they may be included after consultation with the sponsor.\n14. Subjects should provide fresh biopsy tumor tissue specimens prior to treatment.\n\nExclusion Criteria:\n\n1. Receiving concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy); or any investigational therapy within 28 days prior to the first dose of study drug.\n2. Receiving TKI therapy within 8 days prior to the first dose of study drug.\n3. Continuance of toxicities due to prior therapy that do not recover (CTCAE V5.0 Grade\\> 1).\n4. Has difficulty in swallowing, absorbing barrier, or other diseases blocking APG-2449' taken.\n5. Obvious cardiovascular disease history.\n6. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.\n7. Active symptomatic fungal, bacterial and\u002For viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C).\n8. Known allergies to study drug ingredients or their analogs.\n9. Female subjects who are pregnant or breastfeeding, or expecting to become pregnant during the study period.\n10. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may endanger its safety or interfere with the safety assessment of the study drug.\n11. Subjects who have used CYP3A4, CYP2C9, or CYP2C19 moderately potent inhibitors or moderately potent inducers 1 week before receiving the study drug for the first time.\n12. Subjects who used CYP3A4 substrates and narrow treatment window 1 week before the first study drug.",{"count":163,"type":20},165,[23],"APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and\u002For recommended phase 2 dose (RP2D), several phase Ib\u002FII studies will be implemented accordingly.",[167,168,169,170,27],"Advanced Solid Cancer","Non Small Cell Lung Cancer","Esophageal Cancer","Ovarian Cancer","2025-06-16",{"date":173,"type":37},"2025-06-18",{"date":175,"type":37},"2019-05-27",{"date":177,"type":20},"2028-01",{"name":179,"class":180},"Ascentage Pharma Group Inc.","INDUSTRY",9,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":127},"100586059","hemithoracic-arc-radiotherapy-post-pleural-decortication-100586059","NCT06910449","Hemithoracic Arc Radiotherapy Post Pleural Decortication","Hemithoracic Volumetric Modulated Arc Radiotherapy as Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma Phase II Trial","Inclusion Criteria:\n\n* Evidence of metastatic disease.\n* Underwent Pleural decortication.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Poor pulmonary function tests.\n* Recurrent or palliative cases.\n* Inability to attend full course of Radiotherapy or follow up visits.",{"count":190,"type":20},45,[85],"Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with chemotherapy as the mainstay of treatment . the rationale of post operative Radiotherapy is to sterilize the post operative volume to reduce local failure meanwhile minimizing toxicities in this trial we are going to assess the safety and efficacy of Radiotherapy in Mesothelioma patients poat Pleural decortication",[27],"2025-04-06",{"date":196,"type":37},"2025-04-08",{"date":198,"type":37},"2024-11-11",{"date":200,"type":20},"2027-02",{"name":202,"class":44},"Cairo University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":127},"100471953","phase-2-ot-101-in-combination-with-pembrolizumab-in-subjects-with-malignant-pleural-mesothelioma-failing-to-respond-to-checkpoint-inhibition-100471953","NCT05425576","OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition","Phase 2 Trial of TGF-β Inhibition (OT-101) With Anti-PD-1 (Pembrolizumab) in Patients With Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition","Inclusion Criteria:\n\n1. Participants must have progressed on treatment with an anti-PD-1 or anti-PD-L1 mAb or anti-CTLA-4 mAb administered either as monotherapy or in combination with other therapies including platinum-based chemotherapy. PD-1 treatment progression is defined by meeting all of the following criteria:\n\n   a. Has demonstrated disease progression after anti-PD-1 or anti-PD-L1 or anti-CTLA-4 mAb as defined by the investigator.\n2. Male\u002Ffemale participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Malignant Pleural Mesothelioma will be enrolled in this study.\n3. Male participants: A male participant must agree to use contraception as detailed in Appendix 4 of this protocol during the treatment period and for at least 90 days, corresponding to time needed to eliminate any study treatment(s) (e.g. 5 terminal half-lives for pembrolizumab) plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period.\n4. Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) OR\n   2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days\u002Fweeks corresponding to time needed to eliminate any study treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment.\n5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n6. Have measurable disease by Revised mRECIST\n7. Provide a baseline biopsy prior to the start of therapy. Archival biopsy is acceptable.\n8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n9. Have adequate organ function. Specimens must be collected within 10 days prior to the start of study intervention.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to agent administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n2. Has received prior systemic anti-cancer therapy including investigational agents within 28 days prior to study therapy.\n3. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n4. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The following are exceptions to this criterion:\n\n   * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n   * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n   * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n6. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.\n7. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 10 days prior to first dose of study intervention.\n8. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n10. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n11. Has an active infection requiring systemic therapy.\n12. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n15. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n16. Has had an allogenic tissue\u002Fsolid organ transplant.",{"count":211,"type":20},63,[24],"This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.",[27],"2024-03-13",{"date":217,"type":37},"2024-03-15",{"date":219,"type":20},"2025-06",{"date":221,"type":20},"2029-12",{"name":223,"class":180},"Oncotelic Inc."]